Immunocore names AstraZeneca exec as new CEO
January 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Clinical stage biotechnology company Immunocore has announced the appointment of AstraZeneca executive Bahija Jallal as the company’s new CEO. The …
Ironwood Pharmaceuticals names AstraZeneca veteran Mark Mallon as new CEO
January 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, CEO, Ironwood, Sweden, mark mallon
The Cambridge, Massachusetts pharma firm Ironwood Pharmaceuticals has announced the appointment of AstraZeneca veteran Mark Mallon in preparation for the …
Eli Lilly to buy Loxo Oncology in deal worth $8 billion
January 7, 2019Manufacturing and Production Cancer, Eli Lilly, Loxo Oncology, gene therapy, personalised medicine
US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in …
Roche’s Genentech inks potential $2bn personalised cancer drug development deal
January 7, 2019Sales and Marketing Adaptive Biotechnologies, Cancer, Genentech, Roche, oncology, pharma
Roche’s Genentech is set to enter into a deal with Adaptive Biotechnologies to bolster its pursuits in the treatment of …
How tech is powering precision treatment
January 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Precision Medicine, pharma, tech
As the scientific community eschews scattergun approaches and demand rises for higher-quality, targeted care, Matt Fellows explores how technologies such …
Promising interim Phase 3 data spurs epidermolysis bullosa trial expansion for Amryt
January 7, 2019Research and Development, Sales and Marketing Amryt, epidermolysis bullosa, pharma, rare disease
Rare disease firm Amryt has announced interim efficacy data for its epidermolysis bullosa (EB) therapy AP101, showing that things are …
AstraZeneca loses two senior executives as biotechs appoint new CEOs
January 7, 2019Sales and Marketing AstraZeneca, CEO, Ironwood Pharmaceuticals, biotech, immunocore
Two of AstraZeneca’s senior executives have been poached by the biotech firms Ironwood Pharmaceuticals and Immunocore, as the two biotechnology …
$400 billion in healthcare M&A deals expected for 2019
January 7, 2019Sales and Marketing Hong Kong, M&A, MA, biotech, deals pharma, law, mergers
The coming year is set to see mergers and acquisitions in the healthcare sector worth more than $400 billion, according …
Sanofi will pay Regeneron $582m in deal restructuring
January 7, 2019Sales and Marketing Deals, Regeneron, Sanofi, biotech, pharma
French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal …
Aevi Genomic Medicine’s share price crashes 75% following ADHD trial failure
January 4, 2019Medical Communications, Research and Development ADHD, AEVI-001, Aevi Genomic Medicine, clinical trial failure, pharma
Aevi Genomic Medicine, a US drugmaker based outside of Philadelphia, has seen its share value plummet by 75% following the …
NICE recommends AstraZeneca’s Fasenra as third treatment option for severe asthma
January 4, 2019Medical Communications, Sales and Marketing AstraZeneca, Fasenra, NHS, NICE, UK, asthma, pharma
It’s good news for both asthma patients and AstraZeneca after UK drug watchdog NICE saw fit to recommend the drugmaker’s …
MHRA issues recall of irbesartan blood pressure meds over carcinogen contamination concerns
January 4, 2019Manufacturing and Production, Medical Communications MHRA, irbesartan, pharma, sartan, valsartan
Following a number of recalls issued in the US and Europe in the latter half of 2018 for the blood …
Takeda unveils three new discovery and development collaborations in immuno-oncology
January 4, 2019Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma
Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …
BMS to acquire Celgene for $74 billion in biggest-ever pharma deal
January 4, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, acquisition, pharma
Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of …
Children should be given flu vaccine to protect older people
December 21, 2018Medical Communications epidemiology, flu, health, public health, vaccines
Parents are being urged to give their children the flu vaccine in order to protect ‘older people’ from the potentially …
Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus
December 21, 2018Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology
California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …
Top Ten most popular articles on Pharmafile.com of 2018!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Business, biosimilars, brexit, pharma, top 10
Brexit, business and biosimilars, seemed to be the three themes of 2018. As Brexit negotiations reached a stalemate the pharmaceutical …
J&J’s Baby powder tested in India and Bangladesh
December 21, 2018Medical Communications Bangladesh, Cancer, India, J&J, JJ, asbestos
Bangladeshi authorities will collect and test samples of Johnson & Johnson’s baby powders for traces of cancer causing asbestos, after …
Top Ten most popular articles on Pharmafile.com this week!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …
Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million
December 20, 2018Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
